First Eagle Investment Management
XFOR icon

First Eagle Investment Management’s X4 Pharmaceuticals XFOR Stock Holding History

First Eagle Investment Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,191
Closed -$536K – 144
2019
Q2 		$536K Buy
1,191
+500
+72% +$254K ﹤0.01% 144
2019
Q1 		$361K Hold
691
– – ﹤0.01% 150
2018
Q4 		$289K Hold
691
– – ﹤0.01% 160
2018
Q3 		$201K Hold
691
– – ﹤0.01% 168
2018
Q2 		$452K Hold
691
– – ﹤0.01% 164
2018
Q1 		$2.85M Buy
+691
New +$2.01M 0.01% 151

Other funds holding XFOR

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

First Eagle Investment Management's XFOR Position: Q3 2019 in Review

First Eagle Investment Management sold out of X4 Pharmaceuticals (XFOR) in Q3 2019, closing a stake of 1,191 shares — an estimated $536K sold.

First Eagle Investment Management first reported a position in XFOR in Q1 2018 and held it in 6 quarters. The position peaked at $2.85M in Q1 2018. 49 funds tracked by Wall St. Rank hold XFOR as of Q3 2019.

  • First Eagle Investment Management reported no remaining X4 Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • First Eagle Investment Management sold 1,191 X4 Pharmaceuticals shares in Q3 2019, an estimated $536K.
  • First Eagle Investment Management first reported a position in X4 Pharmaceuticals in Q1 2018 and held it in 6 quarters.
  • First Eagle Investment Management's X4 Pharmaceuticals position peaked at $2.85M in Q1 2018.
  • 49 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2019.

Based on First Eagle Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.